44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Cancer & Metastasis Research

Sign up for email alert when new content gets added: Sign up

Receptor binding of a novel bifunctional TGF-β1/PD-L1 fusion protein elicited a downregulated immune signature

Joint Event on 24th International Conference on CANCER RESEARCH AND PHARMACOLOGY & International Congress on STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY

August 5-6, 2019 | Singapore

Marvin I De los Santos

University of the Philippines Diliman, Philippines

Posters & Accepted Abstracts: J Can Res Metastasis

Abstract :

Statement of the Problem: There are more than 80 clinical distinct types of autoimmune diseases (AID) and their collective global prevalence rate have increased to >10%. Until now, treatment regimen has relied heavily on the use of drugs (i.e. NSAIDs, glucocorticoids and DMARDs) that down-regulate the entire body’s immune response. High-dose and long-term medication with these drugs have been found to correlate with susceptibility to infections and tumorigenesis. Preclinical studies targeting the receptors of transforming growth factor superfamily such as TGF-β1 has implicated possible use of this molecule in AID management and treatment. However, researchers have reported several drawbacks of targeting TGF-β1 signaling, as they found its involvement in prevention but not reversal of AID. Another group of immune checkpoint protein, the PD-1/PD-L1 axis, has been found to down-regulate immune response and have clinical implications for treatment of the disease. This study aims to utilize the combinatorial immunedownregulating activities of TGF-β1 and PD-L1 by generating a fusion product which has never been described before.

Methodology: We were able to previously successfully clone and generate a fusion gene construct of TGF-β1 and PD-L, validated by DNA sequencing. The study focused next on characterizing the bifunctional binding of the proteins with their respective receptors by co-immunoprecipitation (co-IP) and reverse co-IP experiments coupled with pathway analysis by qRT-PCR.

Findings and Results: A 70 kDa TGF-β1/PD-L1 fusion protein was demonstrated to bind TGF-β1 receptors such as TGF-β receptor 1 and PD-L1 target receptor, PD-1, in co-IP and reverse co-IP experiments. Gene expression analysis showed that these interactions are functional and elicit gene expression signature that is seen in suppressed immunity using a cell line model.

Conclusion and Significance: TGF-β1/PD-L1 fusion protein may represent a new class of immunotherapy for treatment and management of autoimmune diseases in the future.

Biography :

E-mail: [email protected]

 
Google Scholar citation report
Citations : 681

Journal of Cancer & Metastasis Research received 681 citations as per Google Scholar report

Journal of Cancer & Metastasis Research peer review process verified at publons
Top